Clinigen Group PLC | Cash Flow

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
11,332.00
21,283.00
8,300.00
15,900.00
14,100.00
35,900
Depreciation, Depletion & Amortization
1,876.00
3,502.00
7,500.00
20,800.00
19,200.00
23,800
Other Funds
3,308.00
226.00
5,700.00
5,600.00
22,400.00
3,700
Funds from Operations
16,516.00
24,559.00
21,500.00
42,300.00
55,700.00
56,000
Changes in Working Capital
1,719.00
5,516.00
8,400.00
200.00
9,600.00
8,400
Net Operating Cash Flow
18,235.00
19,043.00
13,100.00
42,100.00
46,100.00
47,600
Capital Expenditures
18,739.00
22,012.00
8,600.00
8,000.00
8,800.00
Net Investing Cash Flow
18,739.00
22,352.00
188,300.00
30,400.00
8,800.00
Cash Dividends Paid - Total
495.00
2,476.00
2,600.00
4,100.00
4,900.00
Issuance/Reduction of Debt, Net
1,626.00
16,500.00
51,500.00
8,500.00
33,400.00
Net Financing Cash Flow
6,572.00
14,024.00
181,300.00
12,300.00
37,800.00
Net Change in Cash
6,129.00
10,461.00
6,000.00
-
-
Free Cash Flow
17,768.00
18,402.00
12,900.00
40,800.00
44,700.00
Net Assets from Acquisitions
-
-
179,700.00
22,400.00
-
Change in Capital Stock
8,693.00
-
132,400.00
300.00
500.00
Exchange Rate Effect
61.00
254.00
100.00
600.00
500.00
Other Uses
-
340.00
-
-
-

About Clinigen Group

View Profile
Address
Pitcairn House
Burton-on-Trent Staffordshire DE14 2WW
United Kingdom
Employees -
Website http://clinigen.co.uk
Updated 07/08/2019
Clinigen Group Plc engages in the provision of pharmaceutical products and services. It operates through the following segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA), Clinigen Specialty Pharmaceuticals (SP), and Link Health Care. The Clinigen CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies.